Literature DB >> 16201895

Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.

Luca Giovanella1, Luca Ceriani, Antonella Ghelfo, Franco Keller.   

Abstract

BACKGROUND: Thyroidectomy followed by administration of large activities of 131I is the treatment of choice for differentiated thyroid carcinomas. Due to its good prognosis, some authors argue that papillary thyroid cancer with a diameter of up to 10 mm can be treated by surgery alone. In the new TNM classification started in 2002, the T1 group now encompasses all tumours with a diameter up to 20 mm, which widens the indications for a conservative approach. In this instance, prognostic markers are needed to better select patients before planning non-aggressive treatment. Serum thyroglobulin plays a pivotal role in thyroid carcinoma management after thyroid ablation (i.e., surgery and radioiodine) but is of limited value before these treatments. However, thyroglobulin assay performed after surgery but before radioiodine treatment has been proven to be useful in predicting the presence/absence of distant metastasis. PATIENTS AND METHODS: Our study was undertaken in patients affected by pT1 papillary thyroid carcinoma to evaluate the predictive value of post-surgery thyroglobulin assay on 1) restaging immediately after radioiodine treatment and 2) restaging at 12 months. We selected 156 patients affected by pT1 histologically proven papillary thyroid carcinoma, submitted to total thyroidectomy. Serum thyroglobulin was assayed by a specific immunoradiometric method 4 weeks after surgery, just before radioiodine administration. Cut-off levels were selected by receiver operating characteristic curve analysis. Thyroglobulin levels were compared to the results of a post-radioiodine treatment scan and 12-month restaging.
RESULTS: Globally, 23 out of 156 patients showed persistent/recurrent disease (15%). Post-surgery thyroglobulin levels above 4.50 microg/L identified 94% of patients with metastasis at post-dose scan, and a level below 3.20 microg/L identified 86% and 93% of relapsed and disease-free patients at 12-month restaging, respectively. Multivariate analysis and Spearman rank correlation showed that the N-status and post-surgery thyroglobulin level are independent prognostic factors.
CONCLUSIONS: The post-surgery thyroglobulin level could be systematically assayed in patients with pT1-papillary thyroid carcinoma and taken into account in planning treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16201895     DOI: 10.1515/CCLM.2005.142

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  12 in total

Review 1.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

2.  Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer.

Authors:  A Polachek; D Hirsch; G Tzvetov; S Grozinsky-Glasberg; I Slutski; J Singer; R Weinstein; I Shimon; C A Benbassat
Journal:  J Endocrinol Invest       Date:  2011-05-30       Impact factor: 4.256

3.  Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.

Authors:  Jiao Li; Jun Liang; Teng Zhao; Yansong Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-16       Impact factor: 9.236

4.  Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.

Authors:  Teng Zhao; Jun Liang; Zhenqing Guo; Jiao Li; Yansong Lin
Journal:  Endocrine       Date:  2016-01-18       Impact factor: 3.633

5.  Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.

Authors:  A Piccardo; F Arecco; S Morbelli; P Bianchi; F Barbera; M Finessi; S Corvisieri; E Pestarino; L Foppiani; G Villavecchia; M Cabria; F Orlandi
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

6.  [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].

Authors:  Joanna Kłubo-Gwieździńska; Roman Junik
Journal:  Endokrynol Pol       Date:  2008 Mar-Apr       Impact factor: 1.582

7.  Malignant struma ovarii: a case report and review of the literature.

Authors:  M L Mattucci; A Dellera; A Guerriero; F Barbieri; L Minnelli; L Furlani
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

8.  Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.

Authors:  Seunggyun Ha; So Won Oh; Yu Kyeong Kim; Do Hoon Koo; Young Ho Jung; Ka Hee Yi; June-Key Chung
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

9.  Early stimulated thyroglobulin for response prediction after recombinant human thyrotropin-aided radioiodine therapy.

Authors:  Hee Jeong Park; Jung-Joon Min; Hee-Seung Bom; Jahae Kim; Ho-Chun Song; Seong Young Kwon
Journal:  Ann Nucl Med       Date:  2017-07-07       Impact factor: 2.668

Review 10.  Risk Stratification in Differentiated Thyroid Cancer: An Ongoing Process.

Authors:  Gal Omry-Orbach
Journal:  Rambam Maimonides Med J       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.